肿瘤细胞治疗研究
英文原题：Targeted antibody therapy as a treatment strategy for aggressive adult T-cell leukemia/lymphoma.
侵袭性成人 T 细胞白血病/淋巴瘤（ATL）的标准治疗是多药化疗，但随着诊断时患者年龄增长，使用更强效的细胞毒性抗癌药物正变得越来越困难。
成人侵袭性T细胞白血病/淋巴瘤（ATL）的标准治疗为多药联合化疗，但患者确诊年龄增长，使得使用更强细胞毒性抗癌药物越来越困难。为克服这一障碍，研究者开发了预计毒性较低的ATL抗体药物。抗CC趋化因子受体4（CCR4）抗体mogamulizumab的问世显著推动了ATL治疗。真实世界数据和II期临床试验提示，mogamulizumab联合化疗用于老年患者具有疗效，且安全性可管理。有趣的是，在存在CCR4突变及皮肤不良事件的病例中，mogamulizumab也表现良好。此外，包括Tax肽树突状细胞疫苗、免疫检查点抑制剂及CAR-T 细胞疗法在内的新兴免疫疗法正在研究中。这些创新方法旨在增强免疫原性反应，为改善这一难治恶性肿瘤的结局带来希望。
The standard treatment for aggressive adult T-cell leukemia/lymphoma (ATL) is multi-agent chemotherapy, but the use of more intense cytotoxic anticancer agents is becoming more difficult with the aging of patients at the time of diagnosis. As a means of overcoming this hurdle, antibody drugs, which are supposed to be less toxic, have been developed for ATL. The advent of the anti-CC chemokine receptor 4 (CCR4) antibody mogamulizumab has significantly advanced ATL treatment. Real-world data and a phase 2 clinical trial suggest the efficacy and manageable safety profile of mogamulizumab with combination chemotherapy in elderly patients. Interestingly, mogamulizumab has performed well in cases with CCR4 mutations and cutaneous adverse events. In addition, emerging immunotherapies, including Tax peptide dendritic cell vaccines, immune checkpoint inhibitors, and Chimeric Antigen Receptor-T cell therapy, are under investigation. These innovative approaches aim to enhance immunogenic responses and offer hope for better outcomes in this challenging malignancy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
